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AbsTRACT
The current management of autoimmunity involves the 
administration of immunosuppressive drugs coupled to 
symptomatic and functional interventions such as anti-
inflammatory therapies and hormone replacement. Given 
the chronic nature of autoimmunity, however, the ideal 
therapeutic strategy would be to reinduce self-tolerance 
before significant tissue damage has accrued. Defects 
in, or defective regulation of, key immune cells such as 
regulatory T cells have been documented in several types of 
human autoimmunity. Consequently, it has been suggested 
that the administration of ex vivo generated, tolerogenic 
immune cell populations could provide a tractable 
therapeutic strategy. Several potentially tolerogenic cellular 
therapies have been developed in recent years; concurrent 
advances in cell manufacturing technologies promise 
scalable, affordable interventions if safety and efficacy can 
be demonstrated. These therapies include mesenchymal 
stromal cells, tolerogenic dendritic cells and regulatory T 
cells. Each has advantages and disadvantages, particularly 
in terms of the requirement for a bespoke versus an ’off-
the-shelf’ treatment but also their suitability in particular 
clinical scenarios. In this review, we examine the current 
evidence for these three types of cellular therapy, in 
the context of a broader discussion around potential 
development pathway(s) and their likely future role. A brief 
overview of preclinical data is followed by a comprehensive 
discussion of human data.
InTRoduCTIon
The complexity of immune tolerance mechanisms 
presents abundant opportunities for its breakdown, 
leading to the development of autoimmunity. In most 
cases, the precise pathogenesis of autoimmunity 
remains unknown but the genetic polymorphisms 
that underpin, for example, rheumatoid arthritis 
(RA), indicate that antigen presentation, cytokine 
dysregulation and the regulation of lymphocyte 
activation all play key roles. Furthermore, the clus-
tering of different autoimmune diseases within 
families attests to common genetic predisposition 
and pathogenic mechanisms. However, for most 
autoimmune diseases, the provoking autoantigen(s) 
have not been defined and, critically, the predilec-
tion for the joint in RA versus the brain in multiple 
sclerosis (MS) versus the pancreas in diabetes 
mellitus remains enigmatic. Ultimately, the immune 
system can be viewed as a delicate balance of activa-
tion vs tolerance, with multiple mechanisms acting 
to maintain homeostasis.
Historically, management of autoimmune disor-
ders involved managing end-organ manifestations 
such as insulin replacement in diabetes and control 
of pain and inflammation in conditions such as 
RA (table 1). During the second half of the 20th 
century the discovery of glucocorticoids and, 
subsequently, immunosuppressant medications 
enabled modification of the autoreactive process 
with reduced tissue damage and even improved 
life expectancy in diseases such as systemic lupus 
erythematosus (SLE). The 21st century has seen the 
biologics revolution with potent, targeted therapies 
that neutralise key proinflammatory cytokines or 
interfere with lymphocytes themselves. And, most 
recently, potent synthetic signalling pathway inhib-
itors are providing a further means to modulate 
immune reactivity.1 Nonetheless, current manage-
ment options rarely lead to cure, or drug-free 
remission, and most patients require long-term 
maintenance therapy to control disease manifesta-
tions. For example, in RA, approximately 30% of 
patients achieve sustained remission, but 50% of 
these will flare if treatment is discontinued. The 
proportion that flare is usually higher once patients 
have moved on to more potent biological therapies.2 
Because immunosuppressants downregulate the 
normal adaptive immune system, it is not surprising 
that several of the therapies in table 1 are associated 
with an enhanced infection risk, including oppor-
tunistic infections, and the development of malig-
nancy. This is in addition to disease comorbidities 
and drug-specific side-effects, for example, with 
chronic glucocorticoids. In extreme cases, haema-
topoietic stem cell transplantation has been used to 
treat autoimmunity but, with rare exceptions, this 
intervention has not proved curative.3 4
The holy grail of treatment for autoimmunity 
would be the reinstatement of immune tolerance. 
So-called therapeutic tolerance induction offers the 
opportunity to ‘reset’ the diseased immune system to 
a state of immune tolerance, theoretically providing 
for long-term, drug-free remission.5 While multiple 
strategies have proven effective in animal models 
of autoimmunity and transplantation, translation to 
the clinic has been slow. Multiple explanations have 
been offered, relating to disease stage, therapeu-
tics employed, and the need for better biomarkers 
of tolerance, among others. Nonetheless, because 
of the slow progress with therapeutics that target 
the immune system, such as biologic drugs and 
peptides, recent strategies have focused on the use 
of tolerogenic cells themselves.
ToleRogenIC Cell Types
In recent years, investigators have turned their atten-
tion to the ex-vivo expansion or differentiation of 
‘tolerogenic’ immune cells, followed by their adoptive 
transfer, as a potential route to therapeutic tolerance 
induction. To a large degree, these strategies have 
been catalysed by advances in bio-manufacturing in 
general, with robust and scalable processes leading 
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Table 1 Current therapeutic options for management of autoimmunity
Therapy Mode of action
Insulin, thyroxine, etc. Replacement therapy
Paracetamol, opiates Analgesia
Non-steroidal anti-inflammatory drugs: aspirin, ibuprofen, diclofenac, 
naproxen, etc.
Anti-inflammatory
COX-2 inhibitors: celecoxib, etc. Anti-inflammatory
Glucocorticoids: prednisolone, prednisone, dexamethasone, etc. Anti-inflammatory, immunosuppressive
DMARDS: MTX, sulphasalazine, leflunomide, hydroxychloroquine, 
azathioprine, mycophenolate mofetil, ciclosporin, etc.
Various, generally not well defined. Anti-inflammatory, 
immunosuppressive, possibly immunomodulatory. Some, such as MTX, 
may have more than one mode of action.
Cytokine blockade (anti-TNF, anti-IL6 receptor) Anti-inflammatory and immunosuppressive, immunomodulatory
B-cell depletion/modulation (anti-CD20, anti-BLyS) Immunosuppressive, immunomodulatory
Costimulation blockade (abatacept) Immunosuppressive, immunomodulatory
Janus kinase inhibitors (tofacitinib, baricitinib, others in development) Anti-inflammatory, immunosuppressive, immunomodulatory
Intravenous immunoglobulins Immunomodulatory (via Fc receptor interactions)
Plasmapheresis Immunosuppressive, immunomodulatory (by removing (auto)
antibodies and other soluble mediators)
For several therapies, particularly DMARDs, the precise mode of action is not known. Immunomodulation denotes that the treatment has a 
specific and defined effect on the immune system.
DMARDs, disease-modifying anti-rheumatic drugs; MTX, methotrexate.
therapies.6 To date, three main types of tolerogenic cell have been 
the focus of therapeutic strategies in humans.
Mesenchymal stromal cells
Mesenchymal stromal cells (MSCs) are spindle-shaped, plas-
tic-adherent, progenitor cells of mesenchymal tissues with 
multipotent differentiation capacity.7 MSCs can modulate 
innate and adaptive immune cells including dendritic cells (DC), 
natural killer cells (NK) cells, macrophages, B-lymphocytes and 
T-lymphocytes. This occurs via both cell-cell contact and para-
crine interactions through several soluble mediators including 
indoleamine-2,3-dioxygenase (IDO), prostaglandin E2 and 
transforming growth factor β.8–10 These and other mechanisms 
have been summarised in figure 1. By definition, MSCs can 
differentiate into bone, chondrocytes and adipose tissue in vitro; 
they are phenotypically positive for CD105, CD73 and CD90 
and negative for haematopoietic markers CD45, CD34, CD14, 
CD11b, CD3 and CD19.7 11 They do not express Class II MHC 
molecules unless stimulated by interferons7 and lack costimula-
tory molecules such as CD40, CD80 and CD86.
Exposure to proinflammatory cytokines IFN-γ, TNF and IL-1β10 
and activation by exogenous/endogenous danger signals such 
as bacterial products and heat shock proteins through Toll-like 
receptor 3 (TLR3) ‘licenses’ MSCs to become immunosuppres-
sive12; in contrast, activation through TLR4 confers a proinflam-
matory signature and, under some conditions, TLR3 signals may 
do the same.12 13 The immunomodulatory functions of MSC 
include their ability to: inhibit T cell proliferation and promote 
their differentiation into regulatory T cells (Tregs);14 inhibit the 
CD4+ T cell induced differentiation of B-cells into plasma cells 
and directly inhibit B-cell proliferation, differentiation and chemo-
taxis.15 Although MSCs reside in most postnatal organs and 
tissues,16 they are readily harvested from bone marrow, adipose 
tissues, umbilical cord blood and Wharton’s jelly (figure 2).
Tolerogenic dendritic cells (toldC)
DCs are best recognised for their antigen presenting functions in 
driving immune responses against pathogens and tumour cells. 
However, DC also play crucial roles in co-ordinating central 
and peripheral tolerance processes, such that absent or deficient 
DC associate with an 
increased tendency to 
develop autoimmu-
nity.17 18 Furthermore, in 
autoimmunity, DC are 
skewed to a proinflam-
matory state, producing 
more proinflammatory 
cytokines and leading to 
activation and differen-
tiation of autoreactive T 
cells.19
Immature DC are 
usually regarded as 
tolerogenic, whereas 
mature DC can exert 
either tolerogenic or 
immunogenic func-
tions depending on 
signals received during 
maturation from the 
microenvironment and 
invading pathogens. 
For instance, bacterial 
l ipopolysaccharides 
induce immunogenic maturation of DC by upregulating surface 
MHC complexes and T cell costimulatory molecules (CD80, 
CD86),20 21 while schistosomal lysophosphatidylserine, anti-in-
flammatory cytokines (eg, IL-10) and glucocorticoids induce 
a tolerogenic phenotype.18 Tolerogenic dendritic cells (tolDC) 
induce peripheral tolerance by induction of anergy and deletion 
of T cells,22 blockade of T cell expansion23 and induction of 
regulatory T cells (Tregs).24 25 Tregs in turn induce the regula-
tory properties of DC (figure 1). These mechanisms have already 
been reviewed.26 27
Several methods can be used to produce stable tolDC ex vivo, 
with limited or no capacity to transdifferentiate into immuno-
genic DC. Common methods include inhibiting the expression 
of immune-stimulatory molecules (CD80/CD86 and IL-2)28–30 
or stimulating constitutive expression of immunosuppressive 
molecules such as IL-4, IL-10 and CTLA-4,31–35 through genetic 
engineering. Also, exposing differentiating DC ex-vivo to drugs 
such as dexamethasone and vitamin D336 37 or immunosuppres-
sive cytokines such as IL-10 and TGF-β38–40 and lipopolysaccha-
rides41 can be used to produce tolDC. These and other methods 
have been extensively reviewed elsewhere.42
Regulatory T cells (Tregs)
Tregs are a subset of T cells expressing CD4, CD25 and intra-
cellular Forkhead Box P3 (FoxP3) protein that inhibit the func-
tions of effector T cells as well as other immune effector cells and 
so are essential for immune tolerance.43 44 They mediate their 
effects by producing immunosuppressive cytokines and by cell-
to-cell contact, following stimulation via their antigen-specific 
T cell receptors (TCR). These mechanisms also modulate other 
immune responses in an antigen-non-specific manner through 
‘bystander suppression’ and ‘infectious tolerance’.45 46 Treg 
depletion and dysfunction have been implicated in a variety of 
autoimmune disorders including type 1 diabetes, RA, SLE and, 
classically, with an inherited deficiency of FoxP3, immune dysreg-
ulation polyendocrinopathy enteropathy X linked syndrome.47 48 
These findings support the possibility that ex-vivo expansion and 
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Figure 1 A schematic representation of the mechanisms of action of tolerogenic cells. MSCs promote the differentiation and survival of Tregs and 
tolDC. Tregs and tolDC, on the other hand, enjoy a mutual bidirectional positive interaction with each other. Tregs and MSCs inhibit the actions of B 
cells, effector T cells, macrophages and neutrophils through cell-cell contact (eg, Fas:Fas Ligand (FasL) mediated deletion), and various soluble factors 
such as TGF-β, IDO, PGE2, IL-10, IL-6, and sHLA-G5. MSCs also act through extracellular vesicles.8–10 18 TolDC directly inhibit effector T cells through 
various mechanisms. These include: cell-cell ligand-receptor mediated deletion, for example, Fas: FASL, PD-L1 and PD-L2 on tolDC and PD-1 receptors 
on effector T cells; effector T cell anergy secondary to low expression of co-stimulatory molecules CD80/CD86, CD40 and pro-inflammatory cytokines 
(TNF, IL-12, IL-21 and IL-16) by tolDC. Other mechanisms include soluble anti-inflammatory cytokines such as IL-10, IL-4 and TGF-β.26 27TolDC directly 
promote Tregs and so indirectly inhibit other immunogenic cells through Tregs. Mechanisms include soluble factors such as IL-10, IDO, TGF-β and 
TSLP and cell-cell interaction between CTLA-4 and CD80/86. This interaction, in turn, leads to transendocytosis of CD80/86 and further tolerogenic 
phenotypic ‘reinforcement’ of tolDC. Tregs also promote tolDC via IL-10 and TGF-β.26 27 CTLA-4, cytotoxic T-lymphocyte associated protein 4; IDO, 
indoleamine-2,3-dioxygenase; IL, interleukin; MSCs, mesenchymal stromal cells; PDL, programmed death ligand; PGE2, prostaglandin E2; sHLA, 
soluble human leucocyte antigen; TGF-β, transforming growth factor beta; tolDC, tolerogenic dendritic cells; TSLP, thymic stromal lymphopoietin.
effective therapeutic strategy for unwanted immunopathology 
such as autoimmunity.
In the past, the lack of reliable Treg surface markers and the 
resultant possibility of simultaneously isolating and transfusing 
proinflammatory T cells slowed the development of protocols 
for Treg isolation and expansion.5 More recent studies have used 
CD4, CD25 and CD127 cell surface markers to isolate CD4+C-
D127lo/-CD25+ Tregs from blood.49 50 Other types of regulatory 
T cells exist, such as T-regulatory type 1 (Tr1) cells, which secrete 
IL-10.51 These are a distinct population of regulatory T cells that 
only transiently express FoxP3, on activation.52 They coexpress 
CD49b and LAG-3, and secrete high levels of IL-10 but low 
amounts of IL-4 and IL-17. Suppression is dependent on IL-10 and 
TGF-β and they kill myeloid antigen-presenting cells via granzyme 
B release.
Migration of tolerogenic cells
MSCs, Tregs and tolDC express a host of homing receptors that 
are important for their transmigration from the tissue of admin-
istration (eg, skin or vascular system) to activation sites (eg, 
regional lymph nodes) and, ultimately, to the target organs. For 
instance, FoxP3+ Tregs express CC receptor 7 (CCR7), CCR4, 
CCR6, CXC receptor 4 (CXCR4) and CXCR5. They also express 
CD103 (integrin αEβ7) (whose ligand is E-cadherin expressed 
by epithelial cells) and CD62L (L-selectin) (whose ligands are 
the lymph node and mucosal lymphoid tissue endothelial cell 
addressins CD34, GlyCAM-1 and MAdCAM-1).53 Activated 
tolDC express CCR7 and migrate to CC chemokine ligand 19 
(CCL19),54 underpinning migration to regional lymph nodes. 
MSCs, on the other hand, express a restricted set of chemo-
kine receptors (CXCR4, CX3CR1, CXCR6, CCR1, CCR7) and 
have shown appreciable chemotactic migration in response to 
the chemokines CXC ligand 12 (CXCL12), CX3CL1, CXCL16, 
CCL3 and CCL19.55 MSCs may also exert tolerogenic effects in 
distant tissues via extracellular vesicles.10 It is clearly important 
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Figure 2 Preparation and administration of tolerogenic cellular therapies. This figure describes the process of cellular therapy manufacture 
and administration. Sources of substrate cells include autologous or allogeneic umbilical cord tissue, bone marrow aspirate and lipo-aspirate for 
mesenchymal stromal cells and autologous whole blood for expanded regulatory T cells and tolerogenic dendritic cells. Mononuclear cells are usually 
extracted by density gradient centrifugation of whole blood, bone marrow aspirate and digested tissue (lipo-aspirate and umbilical cord tissue) 
or by leukapheresis (whole blood). Mononuclear cells are then cultured in the appropriate media and culture conditions for the requisite duration 
or number of passages. Harvested cells can be administered immediately through various routes (subcutaneous, intravenous, intralesional and 
intrathecal) or cryopreserved for future use.
CellulAR THeRApIes FoR THeRApeuTIC ToleRAnCe
What could cellular therapies achieve?
Numerous preclinical studies using animal models of autoim-
mune disorders have shown potent tolerogenic effects of these 
various immune modulatory cells, although some mechanisms of 
action remain unclear. Animal models do not faithfully replicate 
all mechanisms of human autoimmunity but positive results have 
provided the scientific basis to catalyse clinical trials.
Mesenchymal stromal cells (MsCs)
The first ever preclinical study of MSCs in an autoimmune 
setting was in experimental auto-immune encephalomyelitis (a 
model for MS).56 MSCs were effective in treating the disease and 
were shown to be strikingly effective if injected before or at the 
onset of disease. Further studies in experimental MS buttressed 
this finding57–60 and showed that MSCs control disease through 
inhibition of CD4+ Th17 T cells,58 generation of CD4+CD25+-
FoxP3+ Tregs60 and through hepatocyte growth factor produc-
tion.59 Therapeutic efficacy was also observed in the MRL/Lpr61 
and NZB/W F162 63 mouse models of SLE. MSCs were effec-
tive in collagen-induced arthritis,64 65 Freund’s adjuvant-induced 
arthritis and K/BxN mice with spontaneous erosive arthritis.66 
These studies have been reviewed elsewhere.10
Results from early clinical trials in MS showed good tolera-
bility and some potential efficacy67–70 (table 2A) associated with 
increased number of Tregs in the peripheral blood of patients.67 
In the most recent controlled study,70 13 patients received MSCs 
while 10 patients received conventional MS treatment. The 
active treatment group showed a more stable disease course and 
a transient increase in immunomodulatory cytokines. A place-
bo-controlled dose-ranging study of mesenchymal-like cells 
derived from placenta in patients with MS71 used a distinct type 
of cell with immunomodulatory and regenerative properties, 
which do not fully meet ISCT criteria for MSCs (and therefore 
not included in table 2A). Their phenotype includes CD10+, 
CD105+ and CD200+; they are CD34- and, like MSCs, do not 
express class II HLA or costimulatory molecules CD80, CD86. 
The cells appeared safe and well tolerated in patients with 
relapsing remitting MS and secondary progressive MS.
In RA, MSCs were well-tolerated and showed preliminary effi-
cacy with improvements in clinical outcomes when combined 
with disease-modifying anti-rheumatic drugs (DMARDS).72 73 In 
the first placebo-controlled randomised trial of MSCs in RA,73 
40 patients who had failed at least two biological DMARDS 
received intravenous infusions of adipose-derived MSCs at 
varying dose, while 7 patients received placebo. Adverse events 
were few and included fever and respiratory tract infections; 
however, serious adverse events included a lacunar infarction. 
Clinical outcomes, especially DAS28-ESR, showed a dose-de-
pendent improvement.
The first case series of MSC in patients with SLE was published 
in 2009.74 Four patients with cyclophosphamide/glucocorti-
coid-refractory SLE were treated with bone marrow-derived 
MSCs. After 12–18 months of follow-up, all showed improve-
ment in disease activity, renal function and serological markers. 
Subsequent studies, mainly by the same group, have confirmed 
that MSCs are safe in SLE and reported promising results such as 
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Table 2A Clinical trials of mesenchymal stromal cells in MS, RA and SLE
diseases and clinical trials
number of patients, source of cells, dose and route of 
administration outcomes Comments
Multiple sclerosis, MS 
  1. Karussis et al (2010)67
  Phase I/II uncontrolled 
feasibility study of patients 
with MS and ALS
34 patients (15 with MS, 19 with ALS) received autologous 
BM-derived MSCs intrathecally (n=34) at a mean dose of 
63.2×106 in 2mls of saline and intravenously (n=14) at a 
mean dose of 23.4×106 cells in 2mls of saline.
No major AEs. EDSS score improved over 6 months. 
Proportion of CD4+CD25+ Tregs increased, and 
expression of CD40, CD83, CD86 and HLA-DR 
on myeloid dendritic cells decreased 24 hours 
post-administration. MRI of MSC labelled with 
superparamagnetic particles showed MSCs in 
meninges, subarachnoid space, and spinal cord.
No comparison between intravenous and 
Intrathecal routes as regards homing of 
MSCs to the CNS. Cryopreserved cells 
were used.
  2. Bonab et al (2012)68
  Phase II uncontrolled study 
of patients with SPMS
22 patients received Intrathecal, autologous BM-derived 
MSCs at a mean dose of 29.5×106 cells in 10mls of normal 
saline.
AEs were low-grade: transient fever, headache, 
nausea/vomiting (related to lumbar puncture). 
Disease progression stabilised in the short-term 
evidenced by MRI and EDSS score.
After initial improvement some patients 
reported worsening EDSS, and about 25% 
showed worsening lesions on MRI, after 
12 months. Cryopreservation was not 
discussed.
  3. Connick et al (2012)69
  Phase IIa feasibility/ proof-
of-concept study in patients 
with SPMS
10 patients received autologous bone marrow (BM)-derived 
MSCs intravenously at a mean dose of 1.6×106 cells/kg.
Mild AEs such as transient post-transfusion rash and 
self-limiting bacterial infections. Improvement in 
visual acuity, visual evoked potentials, optic nerve 
area and EDSS. No change in post-treatment T cell 
subset counts.
Cryopreserved cells were used.
  4. Li et al (2014)70
  Randomised
  Controlled Phase II study 
in patients with RRMS and 
SPMS
13 patients received 3 cycles of intravenous, allogeneic 
umbilical cord (UC)-derived MSCs, 2 weeks apart, at 
a dose of 4×106 cells/kg body weight in 100mls of 
saline. Conventional treatment (anti-inflammatory and 
immunosuppressants) was continued; 10 patients received 
only conventional treatment.
Reduced frequency of recurrence in the treatment 
group, who also had a more steady disease course. 
No significant adverse event. Transient improvement 
in immunomodulatory cytokines was recorded
Randomised controlled study but not 
blinded. Cryopreservation was not 
discussed
Rheumatoid arthritis 
  5. Wang et al (2013)72
  Phase II non-randomised, 
controlled study
172 patients with active RA. 136 received 4×107 allogeneic 
UC-derived MSCs in 40mls of intravenous saline while 36 
received only saline. All patients continued their DMARDS.
No serious adverse events. TNF-alpha and IL-6 
decreased while FoxP3+ Tregs increased in the 
treatment group after infusion. Better clinical 
outcomes (ACR responses, HAQ and DAS28) after 3 
months in the treatment group
Non-randomised study. Treatment group 
and control group were recruited in 
different time frames. Cryopreserved cells 
were used
  6. Alvaro-Gracia et al 
(2017)73
  Dose-escalation, 
randomised, single-blind 
(double-blind for efficacy), 
phase Ib/IIa study
53 patients with refractory RA (failed two biologics) 
received three intravenous infusions at different doses 
(1×106, 2×106 and 4×106 cells/kg) of allogeneic, adipose-
derived MSCs or placebo
Generally well-tolerated. Mild adverse events. Dose-
dependent response especially DAS28-ESR at 1 
month and 3 months post-infusion. Distribution of T 
cell populations was not significantly modified.
First placebo-controlled study of MSCs 
in RA. 19% of patients generated 
mesenchymal stromal cell-specific anti-
HLA1 antibodies without apparent clinical 
consequences. Cryopreserved cells were 
used
SLE 
  7. Sun et al (2009)74
  Safety of MSC in Patients 
with refractory SLE
Four patients with refractory SLE received intravenous, 
allogeneic BM-derived MSCs at a dose of 1×106 cells/kg.
Safe and well-tolerated. Stable course of SLE disease 
activity by 12–18 months post-treatment, with 
improvement in SLEDAI and serological markers.
First study in SLE. Provided evidence for 
further studies in SLE. Cryopreservation 
was not discussed.
  8. Liang et al (2010)75
  Early phase safety/efficacy 
study in refractory SLE
15 patients with refractory SLE were treated with one 
intravenous infusion of 1×106 cells/kg allogeneic BM-MSC. 
Mean follow-up period of 17.2 months
No serious adverse events. All patients clinically 
improved with decrease in SLEDAI, proteinuria, and 
anti-dsDNA.
Improvement in some patients allowed 
reduction in doses of steroids and 
immunosuppressants. Cryopreservation 
was not discussed.
  9. Sun et al (2010)76
  Early phase I/II study
16 patients with active and refractory SLE on different 
treatment regimens received 1×106 cells/kg intravenous of 
UC-derived MSC.
Significant improvement in SLEDAI score, 
autoantibodies, complement C3 and renal function 
accompanied by increased Tregs.
Patients clinically improved despite 
reducing doses of maintenance 
steroids and immunosuppressants. 
Cryopreservation was not discussed.
  10. Wang et al (2012)77
  Early phase I/II study. 
Compared the efficacy of 
single and double infusions
58 patients with refractory and active SLE. 30 received one 
intravenous dose of 1×106 cells/kg allogeneic BM-MSCs or 
UC-MSCs, while 28 received two infusions of 1×106 cells/
kg 1 week apart.
No remarkable difference in SLEDAI and serological 
marker changes between the two groups.
Non-significance of difference in clinical 
improvement between single and double 
dose cohorts may be related to sample 
size. Cryopreservation was not discussed.
  11. Li et al (2013)78
  Early phase I/II study in 
patients with SLE with 
refractory cytopaenia
35 patients with SLE with refractory cytopaenia received 
1×106 cells/kg of either allogeneic BM-derived or allogeneic 
UC-derived MSCs and followed up for an average of 21 
months.
Well-tolerated. Significant improvement in blood cell 
counts after MSC treatment. Clinical improvement 
was also associated with increased Tregs and 
decreased Th17.
Focused on haematological parameters in 
SLE. Cryopreservation was not discussed.
  12. Wang et al (2013)79
  Early phase I/II 4 year 
single-centre study
87 patients with SLE . Allogeneic BM-MSC or UC-MSC 
infused intravenously at 1×106 cells/kg. Some patients were 
treated with cyclophosphamide to inhibit active lymphocyte 
response. 18 patients received repeat doses of MSC for 
relapses
Generally safe and well-tolerated. SLEDAI score, 
renal function and blood counts significantly 
improved for up to 4 years. All patients underwent 
tapering of steroids and immunosuppressants 
according to clinical status.
No differences in outcomes between those 
pretreated with cyclophosphamide and 
those that were not. No differences with 
regard to source of cells (UC and BM). 
Cryopreservation was not discussed.
  13. Wang et al (2014)80
  Multicentre phase I/II study
40 patients with active and refractory SLE received 
two intravenous doses of 1×106 cells/kg allogeneic 
UC-derived MSCs while still maintaining baseline 
immunosuppressants+/-steroids.
Well-tolerated. 60% achieved major clinical 
response or partial clinical response as determined 
by BILAG scores. SLEDAI, renal function and 
serological indices also improved allowing tapering 
of steroid and immunosuppressant doses.
12.5% and 16.7% relapse rate at 9 and 
12 months, respectively. Cryopreservation 
was not discussed.
ACR, American College of Rheumatology; AE: adverse events; ALS, amyotrophic lateral sclerosis; BM, bone marrow; BILAG, British Isles Lupus Activity Group; DAS28, Disease Activity Score-28 
joint count; EDSS, Expanded Disability Status Score; HAQ, Health Assessment Questionnaires; RA, rheumatoid arthritis; RRMS, relapsing remitting multiple sclerosis; SLEDAI, Systemic Lupus 
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Table 2b Clinical trials of mesenchymal stromal cells in Crohn’s disease
diseases and clinical trials
number of patients, source of cells, dose and 
route of administration outcomes Comments
Crohn’s disease 
  1. Garcia-Olmo et al (2005)82
  Phase I study
5 patients with fistulating Crohn’s disease received 
intralesional injections of autologous adipose derived 
at a dose of between 3 to 30×106 cells depending 
on yield.
Six out of eight fistulae healed completely after 8 
weeks. No adverse effects
First clinical trial of mesenchymal stem 
cells to treat Crohn’s disease. Cells were 
not cryopreserved. Study published before 
the ISCT criteria for MSC was set so cells 
were not assessed against the ISCT criteria.
  2. Garcia-Olmo et al (2009) 83
  Phase II multicentre randomised 
controlled trial
49 patients with complex fistulae. 24 received 
intralesional injection of 20×106 cells/kg allogeneic 
adipose derived stem cells; 25 received fibrin glue.
Significantly better fistula healing in the treatment 
group (relative risk 4.43). Quality of life scores 
were also higher in the treatment group
  3. Duijvestein et al (2010)84
  Phase I study
9 patients with refractory Crohn’s disease received 
two IV infusions of 1–2×106 cells/kg autologous BM-
derived MSCs 7 days apart.
Well tolerated with few mild adverse events such 
as allergic reaction in a patient. Three patients 
showed improvement in Crohn’s disease activity 
indices 6 weeks post-treatment
Three patients required surgery due to 
worsening disease.
  4. Ciccocioppo et al (2011)85
  Phase I/II study in patients with 
fistulating Crohn’s disease
10 patients with refractory Crohn’s disease received 
intralesional injection of autologous BM-derived MSCs 
at a median dose of 20×106 cells every 4 weeks for 
a median four cycles (injections were stopped when 
patients achieved remission or exhausted supplies of 
autologous MSCs).
Clinical improvement in all patients with seven 
achieving complete fistula closure and three 
achieving partial closure. Few adverse events were 
documented. Tregs also increased post-treatment 
and remained stable post follow-up.
Cryopreserved cells were used
  5. Liang et al (2012)86
  Use of MSCs in inflammatory 
bowel diseases
7 patients with inflammatory bowel disease (4 
Crohn’s, three ulcerative colitis) received IV infusion of 
allogeneic BM-derived or UC-derived MSCs at a dose 
of 1×106 cells/kg.
Five patients achieved clinical remission at 3 
months. Endoscopic improvement (assessed by 
endoscopic index of severity score) was also 
observed in three patients.
Cryopreservation was not discussed
  6. de la Portilla et al (2013)87
  Phase I/IIa multicentre study
24 patients received intralesional injections of 
allogeneic adipose derived stem cells at a dose of 
20×106 cells.
More than half of patients showed healing of 
fistulae at 6 months. Up to 30% had complete 
fistula closure
Cryopreserved cells were used
  7. Forbes et al (2014)88
  Phase II open-label multicentre 
study
16 patients with refractory Crohn's disease received IV 
infusion of allogeneic MSCs at a dose of 2×106 cells/
kg weekly for 4 weeks.
Safe and well-tolerated. Clinical improvement 
observed in at least 12 patients, 8 of whom 
achieved clinical remission 42 days post-infusion.
Cryopreserved cells were used
  8. Molendijk et al (2015)89
  Phase I/II double-blind, placebo-
controlled, dose-escalating study
21 patients with refractory fistulating Crohn’s disease 
received intralesional injection of 1×107 or 3×107 or 
9×107 allogeneic BM-derived MSC or placebo.
Well tolerated. More significant fistulae healing in 
all dosing groups when compared with placebo. 
Most observed with 3×107 dose.
Expanded half-products were 
cryopreserved until needed. Two weeks 
before treatment, they were thawed 
and further expanded to yield sufficient 
numbers of cells.
  9. Panés et al (2016)90
  Phase III randomised, double-
blinded controlled study
212 treatment- refractory Crohn’s disease patients 
with fistulae. 107 Patients received 120×106 allogeneic 
adipose derived MSCs as a single intralesional dose, 
while 105 received placebo (saline).
Significantly greater remission rates in the 
treatment group compared with the placebo group. 
Few adverse events notably proctalgia and anal 
abscess.
First phase III study. Effective treatment 
option for Crohn’s disease patients that 
have failed conventional treatment options. 
Cryopreserved cells were used
  10. Dietz et al (2017)91
  Phase I trial of autologous stem 
cells applied in a bio-absorbable 
matrix
12 patients with fistula secondary to Crohn’s disease 
received autologous adipose-derived MSC embedded 
in a Gore Bio-A Fistula Plug through surgical insertion 
at a mean dose of 20×106 per plug
Procedure was safely tolerated and few adverse 
events were reported. 75% of patients achieved 
complete healing at 3 months, while 83.3% 
achieved fistula closure at 6 months.
Cryopreserved cells were used. Thawed 
cells were reincubated with a fistula plug 
in a polypropylene coated bioreactor for 
3–6 days prior to surgery. This is the first 
combination of mesenchymal stromal cells 
in a biomaterial for local application in 
Crohn’s disease.
BM, bone marrow; MSCs, mesenchymal stromal cells; UC, umbilical cord.
indices, anti-dsDNA titre and circulating Tregs.75–80 In the most 
recent multicentre study, up to 60% of treated patients achieved 
either major or partial clinical response as determined by British 
Isles Lupus Activity Group scores.80 However, a relapse rate of 
12.5% at 9 months may warrant repeated infusions of MSCs. An 
analysis, by the same group, of four patients with diffuse alveolar 
haemorrhage in SLE using high resolution CT scan showed reso-
lution of lung pathology after treatment with MSCs.81
A serious complication of Crohn’s disease is perianal fistulae. 
MSCs have been extensively studied in Crohn’s disease for 
their immunomodulatory properties and for their ability to 
differentiate into mesodermal tissues with tissue repair capabil-
ities (table 2B). Results in Crohn’s disease are encouraging with 
patients who received MSCs experiencing significant improve-
ment in fistulae while reporting just minor side effects.82–90 
The unprecedented success of MSCs in a recently concluded 
phase III multicentre clinical study in Crohn’s disease across 
seven European countries and Israel implies that MSCs could 
become a treatment of choice for Crohn’s fistulae refractory 
to conventional treatment. In this study,90 212 patients with 
Crohn’s disease-associated fistulae received intralesional injec-
tions of either MSCs or placebo. Fifty per cent of the treatment 
group achieved combined clinical and radiological remission 
at 24 weeks compared with 34% of the placebo group, with 
only minor adverse effects reported. MSC have also been 
successfully embedded in an absorbable biomaterial and surgi-
cally delivered for the treatment of fistulae associated with 
Crohn’s disease.91 In this study, 12 patients safely received 
MSC embedded in a Gore fistula plug with fistula healing rate 
of 88.3% at 6 months.
MSCs have also been used in several trials to prevent and 
treat graft versus host disease (GVHD). In a multicentre phase 
II study, 55 patients with steroid resistant severe acute GVHD 
received MSCs at a median dose of 1.4×106 cells, obtained 
either from HLA-identical sibling donors, haploidentical donors 
or third-party HLA-mismatched donors. Up to 30 patients 
achieved complete clinical response independent of cell source.92 
In a recent phase II study, prophylactic MSCs were successfully 
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Table 3 Clinical trials of TolDC in autoimmune disorders
diseases and clinical trials
number of patients, source of cells, dose and route 
of administration outcomes Comments
Diabetes mellitus 
  1. Giannoukakis et al (2011)101
  A randomised double-blind 
phase I study
10 patients with type 1 diabetes received 10×106 
autologous peripheral blood-derived dendritic cells 
intradermally every 2 weeks for 4 administrations (7 
received ex vivo manipulated DC lacking CD80/CD86 
while 3 controls received non-manipulated immature 
DCs).
Safely tolerated. Significant increase in the 
proportion of B220+ CD11c- B cells, mainly in 
patients that received manipulated dendritic 
cells. Detectable C-peptide in patients that had 
undetectable pretreatment C-peptide.
First use of tolerogenic dendritic cells in 
human autoimmunity.
Crohn’s disease 
  2. Jauregui-Amezaga et al 
(2015)102
  Phase I dose escalation study
9 patients with refractory Crohn’s disease received 
autologous monocyte-derived tolDC via sonography-
guided intraperitoneal injections in six cohorts: a one-
time injection of 2×106/5×106/10×106 cells for the first 3 
cohorts and three biweekly intraperitoneal injections at 
same escalating doses for another three cohorts.
No adverse effects were detected during 
tolDC injection or follow-up. Some anecdotal 
efficacy was observed and one patient achieved 
remission.
TolDC were not loaded with specific 
antigens. Three patients withdrew due to 
worsening symptoms.
Rheumatoid and inflammatory arthritis 
  3. Benham et al (2015)104
  Phase I randomised controlled 
study
34 patients with RA carrying HLA-DRB1 ‘shared epitope’ 
allele. 18 received autologous monocyte-derived tolDC 
intradermally at a dose of between 0.6 to 4.5×106 cells 
(depending on yield) while 16 were controls
Well tolerated. Low grade adverse events 
including transient leucopoenia, anaemia and 
transaminitis. Treatment was associated with 
reduction in effector T cells and an increased 
regulatory:effector T cell ratio.
First use of dendritic cells for treatment of 
RA. TolDC were exposed to citrullinated 
peptides to confer antigen specificity
  4. Bell et al (2016)103
  Phase I unblinded randomised 
controlled dose escalation study
Monocyte-derived autologous tolDC. Three cohorts of 
patients with rheumatoid or other inflammatory arthritis 
received 1×106, 3×106, or 10×106 cells into an inflamed 
knee. DC exposed to synovial fluid during culture as a 
source of auto-antigen. A fourth (control) cohort received 
arthroscopic washout alone.
Safe and acceptable procedure, feasible to 
manufacture tolDC from peripheral blood of 
patients with arthritis. Arthroscopically assessed 
synovial vascularity and synovitis improved in 
some patients who received TolDC.
First intra-articular administration of tolDC. 
No consistent immunomodulatory trend in 
peripheral blood between treatment and 
control groups. No evidence for DC-induced 
joint flare (indicating DC stability).
TolDC, tolerogenic dendritic cells.
A potential advantage of MSC therapy over some other tolero-
genic therapies is that their lack of MHC class expression means 
that they can be derived from either an autologous or alloge-
neic source with little or no risk of immune rejection.10 Thus, 
cryopreserved allogeneic MSC could become an ‘off-the-shelf ’ 
therapy rather than a bespoke therapy requiring preparation at 
the point of delivery. In tables 2A and 2B, the source of MSC is 
indicated for each trial listed.
Tolerogenic dendritic cells (toldC)
In an early murine experiment, allogeneic DC transfer from 
diabetic non-obese diabetic (NOD) mice to prediabetic NOD 
mice prevented development of diabetes in the latter.94 The 
hypothesis was that the diabetic NOD mice DC contained 
pancreatic antigens that conferred immunoregulatory prop-
erties, possibly by targeting regulatory T cells specific to those 
antigens. Since then, many preclinical studies have demon-
strated that ex vivo generated DC, with an anti-inflammatory 
or tolerogenic phenotype, can effectively suppress or ‘switch 
off ’ auto-immune disorders such as diabetes,95 96 arthritis,97 
MS,98 99 autoimmune thyroiditis100 and myasthenia gravis.39 In 
most studies, tolDC were pulsed with antigens to confer speci-
ficity: bovine serum albumin for bovine serum albumin-induced 
arthritis,97 pancreatic islet lysate for diabetes,95 encephalitogenic 
myelin basic protein peptide 68–86 (MBP 68–86) for MS99 and 
thyroglobulin for autoimmune thyroiditis.100 Interaction of 
autoreactive T cells with such partially mature or ‘deviated’ DC 
results in their loss of functionality (anergy), apoptosis or acqui-
sition of regulatory function. The majority of the studies aimed 
at prevention of autoimmunity by administering tolDC in the 
predisease state (either prophylactically or immediately post-im-
munisation).39 95 96 100 However, tolDC also arrested established 
disease,39 41 97 with similar outcomes to prophylactic models.98 
These studies have been summarised elsewhere.42
The first clinical trial of tolDC in a human autoimmune 
disorder was in type 1 diabetes101 (table 3). In this study, 10 
million autologous DC were safely administered intradermally 
into patients two times a week for a total of 4 doses, without 
serious adverse effects. Two forms of DCs were used: immature 
‘control DC’ cultured from monocyte precursors using IL-4 and 
GM-CSF and immunosuppressive DC (iDC) genetically manip-
ulated ex-vivo to block the expression of costimulatory mole-
cules CD80/CD86.101 TolDC were not loaded with autoantigens 
in this trial. Some therapeutic efficacy was suggested as some 
patients showed elevated c-peptide levels post-treatment, indic-
ative of increased endogenous insulin production. In a phase I 
single centre study, tolDC were also safely infused intraperitone-
ally in patients with refractory Crohn’s disease and showed some 
potential efficacy.102 Other studies of TolDC in autoimmunity are 
in inflammatory arthritis: the AuToDeCRA study where autol-
ogous tolDC were loaded with autologous synovial fluid as a 
source of autoantigen103 and the Rheumavax study where autol-
ogous tolDC were exposed to citrullinated peptides to confer 
antigen specificity and administered intradermally to patients 
with RA.104 In the phase I AuToDeCRA study, DC were injected 
arthroscopically into an inflamed knee joint, as a robust test of 
their stability and safety in an inflamed environment. There was 
no evidence that the procedure provoked a flare of symptoms. 
In a study published only as an abstract, recombinant autoanti-
gen-loaded tolDC were administered subcutaneously to patients 
with RA at doses of 0.5×107 and 1.5×107 cells. Dose-depen-
dent efficacy was reported, especially in autoantigen positive 
patients and autoantibody titres also decreased.105 Other trials 
in Crohn’s disease, RA and MS are ongoing and results are yet 
to be published.27
A potential advantage of (autoantigen-loaded) tolDC compared 
with MSC is their capacity to specifically target autoreactive T 
cells, without non-specific immune suppression.103 104 Other 
similar antigen-specific cells are actively being investigated, 
especially in transplantation. These include regulatory macro-
phages (Mregs),106–108 myeloid derived suppressor cells109 and 
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remain preclinical, regulatory macrophages have been studied in 
humans in the context of renal transplantation. In a recent case 
report,108 two patients received donor-derived Mregs at doses 
of 7.1×106 and 8×106 cells/kg intravenously prior to receiving 
living donor renal transplants. Both patients were eventu-
ally weaned from steroids over 10 weeks leaving maintenance 
low dose tacrolimus. Transfused Mregs were shown to secrete 
IL-10 and suppress T cell proliferation by cell-cell contact and 
IFN-γ induced IDO activity.108 Both patients showed increased 
numbers of circulating Tregs post-transplant and a peripheral 
blood gene expression profile indicative of tolerance according 
to the Indices of Tolerance (IOT) research network.111
Regulatory T cells
‘Natural’ CD4+CD25+FoxP3+ regulatory T cells (Tregs) play a 
central role in immune tolerance in health. While the evidence 
is not always definitive, Treg defects or deficiencies have been 
implicated in several autoimmune diseases.47 112 As with MSCs 
and DCs, considerable effort has therefore been dedicated to 
developing methodologies to isolate and expand these cells, as a 
potential tolerogenic therapy for autoimmune disease. Isolation 
uses the cell surface markers CD4, CD25 and usually CD127low. 
Subsequent expansion generally uses anti-CD3, anti-CD28 and 
IL-2 (figure 2). The expanded cells can, in theory, be rendered 
disease-specific by expansion in the presence of relevant autoan-
tigens or genetic manipulation of TCR expression.113 Expanded 
Tregs have been used preclinically to treat murine models of 
autoimmunity, especially type 1 diabetes114–118 and, in some 
studies, Tregs were expanded with DCs to confer antigen speci-
ficity. In humans, early trials took place in patients with GVHD 
following bone marrow transplantation. For example, transfu-
sion of HLA partially matched allogeneic umbilical cord blood 
derived Tregs at a dose of 0.1–30×105 Treg/kg, following double 
umbilical cord blood transplantation, was associated with a 
reduced incidence of acute GVHD when compared with identi-
cally treated controls without Treg.119 Tregs have also been used 
in a phase I study to prevent GVHD by infusing donor-specific 
ex-vivo expanded Tregs prior to haploidentical haematopoietic 
stem cell transplantation without post-transplantation GVHD 
prophylaxis.120
The first description of expanded Treg administration in 
human autoimmunity was in children with type 1 diabetes.121 
Ten children received intravenous injections of autologous 
Tregs in two dosing cohorts (10×106 and 20×106 cells/kg) and 
followed for 6 months (table 4). A matched control group was 
used to compare clinical improvement after infusion. The treat-
ment group, on average, had lower insulin requirements at 6 
months compared with their matched controls. In an extension 
of this study, a higher dose of up to 30×106 cells/kg was well 
tolerated and associated with some clinical improvement after 
12 months (reduction in insulin requirement and higher C-pep-
tide levels).122 In a recent study in adults with newly diagnosed 
type 1 diabetes,50 a dose escalation protocol was used to assess 
the maximum tolerated dose of Tregs. Patients received intra-
venous infusions of Tregs up to a target dose of 2.3×109 cells, 
experiencing no serious adverse effects. In vitro analysis showed 
that expansion of the Tregs increased the overall number of cells 
and their functional activity/potency. In this study, the DNA of 
expanded Tregs was labelled with deuterium, allowing in vivo 
tracking. Up to 25% of transfused Tregs survived in the periph-
eral blood after 1 year. Furthermore, deuterium did not appear 
in other lymphocyte populations suggesting expanded Tregs 
were stable after administration. Autologous Tr1 cells were also 
well tolerated when administered intravenously in 20 patients 
with Crohn’s disease with associated improvement in disease 
activity.123
Concerns have been raised about the potential plasticity of 
Tregs in relation to their reliability as a cellular therapy. Natural 
Tregs form a relatively small proportion of peripheral blood 
CD4+ T cells and express no unique surface marker to facili-
tate their isolation. Nonetheless, enrichment of CD127-/low cells 
generally suffices to minimise contamination with activated T 
cells. However, the propensity for expanded Tregs to express 
IL-17 was noted some years ago, with evidence suggesting that 
CD4+CD25+FoxP3+ Tregs can undergo transformation to 
pathogenic Th17 cells after repeated expansion.124–126 These 
studies demonstrated that epigenetic instability of the FoxP3 
and retinoic acid receptor-related orphan receptor (RORC) 
loci accounted for the potential for Th17 (de-)differentiation. 
Further investigation demonstrated that both loci were stable 
in ‘naïve’ (CD45RA+) Tregs, when compared with memory 
(CD45RO+) Tregs.126 127 Therefore, use of CD45RA as an addi-
tional marker for Treg isolation should minimise expansion-in-
duced epigenetic instability and produce a more homogenous 
tolerogenic Treg population, with low risk of Th17 transfor-
mation. In mice, evidence exists for cells that coexpress FoxP3 
and RORγT, the murine equivalent of the Th17-lineage defining 
marker RORC.128 Despite a capacity to differentiate into either 
classical Tregs or Th17 cells, these cells demonstrated a regula-
tory function in murine diabetes.
The development of Tr1 cells as a therapy is at an earlier stage 
than regulatory T cell therapy. They can be expanded ex vivo 
from PBMC or CD4+ T cells. One method, using an IL-10 
secreting DC (DC-10), can generate allospecific Tr1 cells for 
potential use in haematological or solid organ transplantation. 
An alternative technique generated ova-specific Tr1 cells for a 
phase 1b/2a clinical trial in Crohn’s disease.123
In vivo expansion of regulatory T cells
IL-2 is a key cytokine for T cell activation and proliferation. 
Furthermore, because natural Tregs express high levels of CD25, 
the IL-2 receptor alpha chain, they are highly sensitive to stim-
ulation by IL-2. In patients with cancer treated with peptide 
vaccine129 and DC-based vaccine immunotherapy,130 131 adminis-
tration of IL-2 (with a rationale to expand effector T cells) actu-
ally led to in-vivo expansion of Tregs. This led to the theory that 
IL-2, particularly at low doses, will preferentially expand Tregs, 
informing preclinical experiments and clinical trials in autoim-
munity. In a cohort of patients with chronic refractory GVHD, 
low dose IL-2 administration (0.3–1×106 IU/m2) increased 
Treg:Teff ratio, with improvement in clinical symptoms and 
enabling tapering of steroid dose by a mean of 60%.132 Similarly, 
low dose IL-2 (1–2×105 IU/m2) post-allogeneic SCT in children 
prevented acute GVHD when compared with those who did not 
receive low dose IL-2.133
Treatment of patients with Hepatitis C virus-induced, cryo-
globulin-associated vasculitis with IL-2 at a dose of 1.5×106 
IU once a day for 5 days followed by 3×106 IU for 5 days on 
weeks 3, 6 and 9 was associated with clinical improvement in 
80% of patients as well as a reduction in cryoglobulinaemia 
and normalisation of complement levels.134 In a phase I trial in 
type 1 diabetes, administration of 2–4 mg/day of rapamycin and 
4.5×106 IU IL-2 thrice per week for 1 month led to a transient 
increase in Tregs but a paradoxical worsening of β-cell function, 
associated with an increase in circulating NK-cells and eosino-
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Table 4 Clinical trials with expanded regulatory T cells (Tregs) in autoimmunity
diseases and clinical trials
number of patients, source of cells, dose and route of 
administration outcomes Comments
ex-vivo expanded Tregs 
Diabetes 
  1. Marek-Trzonkowska et al 
(2012)121
  Phase I non-randomised 
study
10 children with type 1 diabetes received autologous Tregs 
intravenously in two dosing cohorts (10×106 and 20×106 cells/
kg body weight). A matched control group of 10 children did 
not receive a placebo. In the extension study,122 two extra 
patients were recruited for treatment, and 6 out of the total 12 
patients received an additional infusion at 6–9 months (either 
10×106 or 20×106 cells/kg) making up a total dose of 30×106 
cells/kg. Here, patients were followed up for 1 year.
No serious adverse events. Generally, treated children 
had lower insulin requirements at 6 months compared 
with matched controls, and recorded significantly 
higher c-peptide levels. A higher dose of 30×106 cells/
kg was also safely tolerated and was associated with 
better clinical outcomes (more patients in this group 
achieved remission, at 1 year with highest fasting and 
stimulated c-peptide levels and lowest HbA1C levels.
First in-human study of Tregs for 
autoimmunity
  2. Bluestone et al (2015)50
  Phase I dose-escalation 
study
14 adults with type 1 diabetes received intravenous autologous 
polyclonal Tregs in four dosing cohorts (0.056 to 23.5×108 
cells).
Safe. Transferred Tregs were long-lived and stable, with 
up to 25% surviving up to 1 year. Small sample size 
and heterogeneity of diabetes did not allow for efficacy 
assessment
Expanded Tregs had up to 4–8-fold 
higher suppressive activity than 
non-expanded Tregs from the same 
individual
Crohn’s disease 
  3. Desreumaux et al 
(2012)123
  Phase I/IIa multicentre study
20 patients with refractory Crohn’s disease received 
intravenously ovalbumin-specific Tr1 cells at 4 dose cohorts 
(106, 107, 108, 109 cells)
Safely tolerated with few adverse events. Clinical 
improvement with a reduction in Crohn’s disease 
activity index and inflammatory bowel disease 
questionnaires
First in human study of use of Tr1 
cells for treatment of autoimmunity. 
Authors argue that ovalbumin is 
widely distributed in the GI tract 
and will activate Tr1 cells.
In-vivo expanded Tregs 
HCV-induced vasculitis 
  4. Saadoun et al (2011)134
  Phase I/IIa study in HCV-
induced vasculitis
10 patients with HCV-induced vasculitis refractory to HCV 
therapy received 1.5×106 IU subcutaneous (SC) IL-2 daily for 5 
days, followed by three 5 day courses of 3×106 IU/day at weeks 
3, 6 and 9.
Safe with no major adverse events. There was a 
reduction in cryoglobulinaemia in 90% of patients and 
improvement in vasculitis in 80%. FoxP3+ Tregs also 
increased in peripheral blood.
Treatment did not induce effector 
T cell activation, vasculitis flare, or 
increased HCV viremia
Diabetes 
  5. Long et al (2012)135
  Phase 1 study in type 1 
diabetes
9 patients with type 1 diabetes received 2–4 mg/day rapamycin 
for 3 months and 4.5×106 IU IL-2 SC. thrice weekly for 1 month,
Safe with transient Treg increase in the first month but 
clinical and metabolic data showed worsening of β-cell 
function in all subjects.
No change in effector T cell 
frequencies but eosinophils and 
natural killer cells increased.
  6. Hartemann et al (2013)158
  Phase I/II randomised, 
double-blind placebo-
controlled study in diabetes
24 patients with type 1 diabetes received either a placebo or 
one of three doses of IL-2. (0.33×106 IU/day, 1×106 IU/day or 
3×106 IU/day) SC for 5 days
Well-tolerated and few treatment related adverse 
events were reported (flu-like symptoms and injection 
site reactions). There was a significant dose-dependent 
increase in the proportion of Tregs in peripheral blood 
of patients.
  7. Todd et al (2016)140
  Phase I/II non-randomised, 
open label, adaptive dose-
finding trial
40 adults with type 1 diabetes received one injection of IL-2 
SC in different dosing cohorts (0.04×106 to 1.5×106 IU/m2) 
and followed up for 7 days. The end point was the maximum 
percentage increase in Tregs (CD3+CD4+CD25highCD127low) from 
baseline frequency.
Well-tolerated. Optimum dose of IL-2 to induce 10% 
and 20% increases in Tregs were 0.101×106 IU/m2 and 
0.497×106 IU/m2, respectively.
First adaptive dose-finding trial of 
IL-2 in diabetes.
  8. Seelig et al (2017) 142
  Phase I/II response-adaptive 
trial of repeat doses of IL-2 
in diabetes
36 patients with type 1 diabetes received IL-2 at different dose-
frequency combinations. Preliminary analysis of all accumulated 
data after completion of each cohort informed dose-frequencies 
of the following cohort. An initial learning phase involved 
12 participants. Subsequent confirmatory cohorts were eight 
patients each.
Well tolerated apart from injection site reactions. The 
optimum regimen to maintain a steady state increase 
in Treg of 30% and CD25 expression of 25% without 
Teff expansion was 0.26×10 IU/m2 every 3 days.
Preprint data at the time of this 
review
ALOPECIA AREATA 
  9. Castela et al (2014)159
  Case series of low dose IL-2 
in alopecia areata
5 patients received 1.5×106 IU/day IL-2 SC for 5 days followed 
by 3 courses of 3×106 IU/day at weeks 3, 6, and 9.
Safe with improvement in severity of alopecia 
tool (SALT) score (evaluated by two independent 
investigators). Significant increase in the number of 
Tregs was also seen in 80% of patients.
SLE 
  10. Humrich et al (2015)137
  A case report of low-dose 
IL-2 in a patient with 
refractory SLE
1 patient received four treatment cycles of 1.5x106 or 3x106 IU 
IL-2 SC for five consecutive days with a washout period of 9–16 
days after each course.
Clinical improvement was observed with reduction in 
anti-ds-DNA titre and SLEDAI score,
First evidence of possible 
therapeutic effect of low dose IL-2 
in SLE.
  11. von Spee-Mayer et al 
(2016)136
  Phase I study in refractory 
SLE.
5 patients with refractory SLE were treated daily with 1.5×106 
IU IL-2 SC for five consecutive days
Safe with increased CD25 expression in Tregs and 
increased number of FoxP3+CD25highCD27low Tregs 
during the treatment course.
  12. He et al (2016)138
  Phase I study in active SLE
40 patients were treated with 3 courses of IL-2. Each course 
consisted of 1×106 IU IL-2 SC alternate days for 2 weeks, with a 
2 week drug-free period.
Treatment was safe and associated with a significant 
increase in CD25highCD127low Tregs in the CD4+ T cell 
population. Significant clinical improvement was also 
observed such that up to 89.5% of patients had at 
least a 4-point decrease (SRI-4) in the SLEDAI after 12 
weeks.
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appears secondary to defective endogenous IL-2 production.136 
Exogenous low dose IL-2 appears to both reverse the biological 
defect and provide a potential therapeutic strategy.136–138
A common finding in trials of low dose IL-2 to treat autoim-
munity is that effects are transient, declining once treatment is 
discontinued. Effects may not be limited to natural Tregs but also 
extend to FoxP3+CD8+ T cells, at least in type 1 diabetes.139 
However, an optimum dosing regime is yet to be defined. Results 
from a recent adaptive dose-finding study in 40 patients with 
type 1 diabetes suggest that the optimal dose of a single injection 
of IL-2 that will induce 10% and 20% increases in Tregs over 
7 days were approximately 0.10×106 IU/m2 and 0.5×106 IU/
m2, respectively.140 This study also showed that the mean plasma 
concentrations of IL-2 at 90 min postinjection, even at the lowest 
doses, were higher than the hypothetical Treg-specific thera-
peutic window determined in vitro (0.015–0.24 IU/mL). This 
was associated with a dose-dependent transient desensitisation 
of Tregs (downmodulation of the beta subunit of IL-2 receptor 
(CD122)) and a decrease in the number of circulating Tregs and 
other lymphocytes, which improved 2 days after injection. These 
findings may explain the lack of response seen in some patients 
who have received daily injections of low-dose IL-2. A follow-on 
study by the same group investigated the optimum frequency of 
administration of IL-2 in type 1 diabetes.141 Results show that 
the optimum regimen to maintain a steady state increase in Treg 
of 30% and CD25 expression of 25% without Teff expansion 
was 0.26×10 IU/m2 every 3 days.142
It is unclear at this juncture whether in vivo expansion of Tregs 
might provide a superior therapeutic option in autoimmunity 
than ex vivo expansion and readministration. Conceivably the 
two modalities could be combined. Other attempts have been 
made to expand Tregs in vivo. One method is the administra-
tion of autoantigen in Freund’s incomplete adjuvant. In a phase 
I trial, a single dose of insulin-β-chain in IFA was administered 
intramuscularly to patients with type 1 diabetes.143 Treatment 
was well tolerated and appeared to stimulate robust antigen-spe-
cific regulatory T cell populations in the treatment arm up to 24 
months, although there was no statistically significant difference 
in mixed meal stimulated c-peptide responses compared with the 
control group. Other methods are the probiotic use of whole 
helminths or their unfractionated products and administration 
of purified excretory/secretory helminths’ products. In preclin-
ical studies using animal models of RA, MS, Crohn’s disease and 
type 1 diabetes, they induce Tregs (and other regulatory cells) 
in vivo and prevent autoimmunity.144–146 However, clinical trials 
are yet to show consistent encouraging results in humans.145
WHeRe ARe We noW?
Results to date from human clinical trials have shown that cellular 
therapies are, at minimum, safe and feasible, and therefore 
worth exploring further in our pursuit of therapeutic tolerance 
induction. The regenerative properties of MSCs could addi-
tionally provide an element of tissue replenishment, repairing 
some of the damage that inevitably accompanies autoimmunity. 
However, most of the studies outlined in this review are at the 
very earliest phases of clinical development. Phase II and, ulti-
mately, phase III studies will be needed to confirm their efficacy. 
Furthermore, as with any tolerogenic therapy in autoimmunity, 
clear objectives are required for efficacy trials. In transplanta-
tion, ‘operational tolerance’ is present when immunosuppres-
sion can be removed without allograft rejection. The situation 
is less clear in autoimmunity. Re-establishment of self-tolerance 
should equate with life-time drug-free remission, which has been 
demonstrated in some animal models when tolerogenic cells 
are administered both prophylactically and therapeutically.42 95 
However, tolerance takes time to develop and tolerogenic ther-
apies may not reduce symptoms in the short-term, necessitating 
the temporary continuation of more conventional therapies. 
Furthermore, immunosuppressive drugs and glucocorticoids 
could potentially interfere with tolerance induction as previ-
ously suggested for calcineurin inhibitors.147 Careful clinical 
trial designs will therefore be fundamental in order to identify, 
robustly, tolerance induction. In the short term, this is likely 
to require immune monitoring, for example, using autoanti-
body arrays and MHC-peptide tetramers, in order to track and 
interrogate the quality and quantity of the autoantigen-specific 
response.148 149 To date, cellular therapy trials have only occa-
sionally incorporated experimental medicine end-points, for 
example, to measure longevity of cells, their distribution in vivo 
or to determine appropriate dosage.123 140 It is important that 
future trials adopt a similar philosophy, both to advance thera-
peutic development and also for ethical reasons.
Other factors to consider during the development of tolero-
genic cellular therapies include the route of delivery. For more 
standard therapeutics, the main decision is usually oral vs paren-
teral delivery. For cellular therapies, the route has to be paren-
teral but the decision is potentially more sophisticated. For 
example, where might TolDC regulate an aberrant autoimmune 
response? In the target tissue, the draining lymph nodes, the 
central lymphoid organs? Route of delivery is likely to influence 
the therapy's ultimate destination, and treatment development 
needs to encompass work that demonstrates the cells express 
appropriate homing receptors. And then, there are the more stan-
dard developmental questions such as dosage and frequency of 
administration—a true tolerogenic therapy should only require 
a single ‘course’ of treatment but, in a patient with a propen-
sity to autoimmunity, regular re-treatments may be required to 
keep autoreactivity at bay. Choice of autoantigen is also critical 
for certain cellular therapies. And last, cost-effectiveness has to 
be demonstrated for any novel treatment. However, the health 
economics would be very different for a tolerogenic therapy if 
it could truly avoid the need for chronic immunosuppressive 
therapy and its complications, not to mention the ravages of 
autoimmunity-associated tissue damage and comorbidities, such 
as cardiovascular disease.
The costs of isolating and expanding cells for therapy are 
significant but collaborations across academic research centres 
and commercial partners will solve some logistical challenges of 
clinical grade manufacture. Such challenges include cell source, 
cell isolation and expansion techniques, culture media and 
reagents, potency markers and genetic manipulation techniques 
where required (figure 2). These need to be standardised to 
ensure reproducibility because different cell manufacturing tech-
niques will lead to subtle or even unidentified phenotypic differ-
ences in the final product. For example, it is unclear whether 
different types of tolDC, manufactured using distinct techniques, 
will have significantly different clinical effects.150 Measurement 
of potency is therefore a critical step prior to the release and 
administration of any cellular therapy product.151
At one point, the costs of cell manufacturing were envisaged to 
be a potential barrier to the development of immunomodulatory 
cell therapies. However, with the success of cellular therapeutics 
such as chimeric antigen receptor T cells for cancer, significant 
investment has been made in relevant technologies. For example, 
closed bioreactors can enable manufacture of large quantities of 
GMP-grade cells within a shorter period of time than labour-in-
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are inherently adaptable, and therefore transferrable to different 
types of cellular therapy,153 helping to achieve cost-effectiveness 
and reducing batch-to-batch variability.
Eventually, and assuming positive results, comparative effec-
tiveness trials across cell types (MSCs, TolDC and Tregs) may 
be required to determine which products are best suited for 
different forms and stages of autoimmunity. For example, MSCs, 
because of their regenerative capacity, may be favoured in condi-
tions such as Crohn’s disease and MS where tissue regeneration 
would be advantageous. On the contrary, Tregs may be preferred 
in diseases with documented evidence of Treg dysfunction such 
as type 1 diabetes and SLE, because ex-vivo expansion of Tregs 
can reverse Treg dysfunction.154 The effects of different cell types 
is being investigated in transplantation in The ONE Study.155 In 
this collaborative study, different immunosuppressive cell popu-
lations (tolerogenic macrophages, myeloid derived suppressor 
cells, tolDC, monocytes conditioned by MSCs, IL-10 induced 
DCs and rapamycin-conditioned DCs) are manufactured from 
the same leukapheresis product, removing one element of vari-
ability when comparing these very different therapies. Cells are 
then studied in different disease contexts to determine the best 
approach to treatment. It may also prove possible to combine 
different cells to produce synergistic effects.
As tolerance can break down many years before the onset of 
clinical disease, it is also important to consider the optimal timing 
of cellular therapies. Detection of preclinical autoimmunity may 
provide a window of opportunity to treat and cure these diseases 
with safe interventions before symptom onset and before tissue 
damage has accrued. Epitope spreading, with broadening of 
the autoimmune repertoire alongside the non-specific effects 
of tissue damage, might render therapeutic tolerance induction 
more difficult in established disease, despite phenomena such 
as infectious tolerance and linked suppression.156 Appropriate 
immune monitoring will be even more important in disease, 
as a means to establish benefit in the absence of symptoms or 
signs. In-depth studies of allograft recipients who have achieved 
operational tolerance have identified biomarkers that appear 
specific for the tolerant state. These may be useful for moni-
toring attempts at tolerance induction prospectively.157
ConClusIon
It is an exciting time for tolerogenic cellular therapies. Rapid 
advances can be expected in the short to medium term catalysed 
by progress in manufacturing technologies, advances in the devel-
opment of immune monitoring techniques and the identification 
of tolerance biomarkers, alongside an acceptance that earlier 
treatment may be ethically justified if the therapeutic target is 
tolerance induction. Whether any, or all, of the cells discussed in 
this review will ultimately demonstrate robust tolerogenic effects 
must await formal clinical trials of efficacy; and we should be as 
certain as we can be that the timing, route and dosing of therapy 
is optimal before conducting the ‘definitive’ studies. These are 
not easy challenges but they are tractable and, currently, there 
is a large amount of intellectual energy directed at solving them.
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